Loprinzi C L, Carbone P P
Cancer Chemother Biol Response Modif. 1987;9:338-57.
This year, manuscripts addressed numerous pertinent breast cancer issues. Notable conclusions from each of the discussed sections suggest that: (a) oral contraceptives do not increase a woman's risk for breast cancer; (b) the vast majority of women with resected premalignant breast lesions do well for prolonged periods after diagnosis regardless of therapy; (c) satisfactory cosmetic results can occur with either lumpectomy, axillary nodal dissection, and radiotherapy or with mastectomy and breast reconstruction; (d) the primary tumor thymidine labeling index can give prognostic information; (e) immunohistochemical methods can accurately measure tumor estrogen receptors; (f) there are multiple hormonal therapies of similar efficacy; (g) two new single agent chemotherapy drugs deserving further investigation are idarubicin and lonidamine; (h) none of several combination chemotherapy regimens is clearly superior to any of the other 'standard' regimens; (i) there is a lack of consensus among the conclusions of recent adjuvant breast cancer consensus conferences held in the United States and London; (j) inflammatory breast cancer patients treated with initial combination chemotherapy consistently appear to have improved relapse-free and overall survivals when compared to historical controls; and (k) the prognosis in locally recurrent breast cancer patients is better in those previously treated with lumpectomy and irradiation when compared to those previously treated with mastectomy.
今年，手稿涉及了众多相关的乳腺癌问题。各讨论部分得出的显著结论表明：（a）口服避孕药不会增加女性患乳腺癌的风险；（b）绝大多数切除了癌前乳腺病变的女性在诊断后无论接受何种治疗，长期预后都良好；（c）保乳手术、腋窝淋巴结清扫和放疗或乳房切除术及乳房重建都能取得满意的美容效果；（d）原发肿瘤胸腺嘧啶标记指数可提供预后信息；（e）免疫组化方法可准确测量肿瘤雌激素受体；（f）有多种疗效相似的激素疗法；（g）两种值得进一步研究的新型单药化疗药物是伊达比星和氯尼达明；（h）几种联合化疗方案中没有一种明显优于其他任何“标准”方案；（i）美国和伦敦近期召开的辅助性乳腺癌共识会议的结论缺乏一致性；（j）与历史对照相比，接受初始联合化疗的炎性乳腺癌患者的无复发生存率和总生存率持续改善；（k）与接受乳房切除术的患者相比，先前接受保乳手术和放疗的局部复发性乳腺癌患者的预后更好。
